Granisetron: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Granisetron. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Asthenia | 45% |
| Constipation | 18% |
| Somnolence | 15% |
| Headache | 14% |
| Diarrhea | 10% |
| Abdominal pain | 6% |
| Dyspepsia | 6% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Granisetron is indicated for the prevention of: Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.
Source: FDA labeling via NIH DailyMed (set 2758eb4d…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.